Bradycardia News and Research

RSS

Bradycardia, ("heart slowness"), as applied to adult medicine, is defined as a resting heart rate of under 60 beats per minute, though it is seldom symptomatic until the rate drops below 50 beat/min.

New leadless pacemakers carry reduced risks of complications and are less invasive

Loyola Medicine is now offering select heart patients leadless pacemakers that are less invasive and cause fewer complications than standard pacemakers.

9 Apr 2018

ACADIA Pharmaceuticals announces results from Phase II study of antipsychotic in Alzheimer's disease psychosis

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the presentation of data from the Phase II -019 Study of pimavanserin in Alzheimer's disease psychosis at the 10th Clinical Trials on Alzheimer's Disease meeting in Boston.

3 Nov 2017

World’s smallest pacemaker for cardiology patients now offered at Medical City Dallas

Medical City Dallas is now offering the world’s smallest pacemaker for cardiology patients. The Micra pacemaker is a new type of heart device that provides patients with the most advanced pacing technology at one-tenth the size of a traditional pacemaker.

6 Oct 2017

U.S. FDA approves updated labeling for pan-genotypic single tablet regimen for HCV/HIV co-infected patients

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved updated labeling for Epclusa (sofosbuvir 400mg/velpatasvir 100mg), the first all-oral, pan-genotypic, once-daily single tablet regimen (STR) for the treatment of adults with chronic hepatitis C virus (HCV) infection, to include use in patients co-infected with HIV.

1 Aug 2017

Pacemakers and other cardiac devices reveal time, cause of death in some forensic cases

Pacemakers and other cardiac devices can help solve forensic cases, according to a study presented today at EHRA EUROPACE - CARDIOSTIM 2017. Devices revealed the time and cause of death in some cases where autopsy failed to do so.

20 Jun 2017

Takeda announces accelerated approval from FDA for new lung cancer treatment

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that ALUNBRIG (brigatinib) has received Accelerated Approval from the U.S. Food and Drug Administration for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer who have progressed on or are intolerant to crizotinib.

28 Apr 2017

FDA approves first drug for treating rare form of Batten disease

The U.S. Food and Drug Administration today approved Brineura (cerliponase alfa) as a treatment for a specific form of Batten disease. Brineura is the first FDA-approved treatment to slow loss of walking ability in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase-1 (TPP1) deficiency.

27 Apr 2017

Pacing program can lead to seven-fold reduction in fainting episodes

Patients with recurrent fainting episodes (syncope) who received a pacemaker delivering a pacing program designed to detect and stop the abnormal heart rhythms that precede syncope had a seven-fold reduction in fainting compared with patients in a placebo pacing group, according to research presented at the American College of Cardiology's 66th Annual Scientific Session.

20 Mar 2017

Scientists create organ-on-a-chip that can mimic heart's biomechanical properties

The human heart beats more than 2.5 billion times in an average lifetime. Now scientists at Vanderbilt University have created a three-dimensional organ-on-a-chip that can mimic the heart's amazing biomechanical properties.

23 Feb 2017

Houston Methodist offers world's smallest heart device for patients with bradycardia

Houston Methodist Hospital is one of the first hospitals in Texas to offer the world's smallest pacemaker for patients with bradycardia, a condition characterized by a slow heart rate, usually fewer than 60 beats per minute.

2 Feb 2017

Epclusa drug receives FDA approval for treating adult patients with chronic HCV

The U.S. Food and Drug Administration approved Epclusa to treat adult patients with chronic hepatitis C virus (HCV) both with and without cirrhosis (advanced liver disease).

28 Jun 2016

Micra Transcatheter Pacing System approved to treat heart rhythm disorders

The U.S. Food and Drug Administration today approved the first pacemaker that does not require the use of wired leads to provide an electrical connection between the pulse-generating device and the heart. While the Micra Transcatheter Pacing System works like other pacemakers to regulate heart rate, the self-contained, inch-long device is implanted directly in the right ventricle chamber of the heart.

7 Apr 2016

Bradycardia does not increase cardiovascular disease risk

Bradycardia - a slower than normal heartbeat - does not increase the risk of developing cardiovascular disease, according to a study conducted by researchers at Wake Forest Baptist Medical Center. The study is published in the Jan.19 online edition of the Journal of American Medical Association Internal Medicine.

19 Jan 2016

Bridion injection approved to reverse effects of neuromuscular blocking drugs used during certain types of surgery

The U.S. Food and Drug Administration today approved Bridion (sugammadex) injection to reverse the effects of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide, which are used during certain types of surgery in adults.

16 Dec 2015

Egalet, Teva sign agreement to commercialize SPRIX Nasal Spray in Israel, Gaza and the West Bank

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced a collaboration agreement with Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company.

14 Dec 2015

Second-line bosutinib offers ‘durable’ response for chronic phase CML patients

Four-year results for an ongoing study of second-line bosutinib indicate that the tyrosine kinase inhibitor offers long-term efficacy with manageable side effects for patients with chronic phase chronic myeloid leukaemia.

27 Nov 2015

Mylan releases Clozapine Orally Disintegrating Tablets in U.S.

Mylan N.V. today announced the U.S. launch of Clozapine Orally Disintegrating Tablets, 25 mg and 100 mg, the generic version of Jazz Pharmaceutical's FazaClo.

24 Nov 2015

Vibration-based technology reduces apneic events, improves critical clinical parameters in premature infants

Scientists and clinicians at the University of Massachusetts Medical School, Wyss Institute for Biologically Inspired Engineering, and the Beth Israel Deaconess Medical Center have shown in a clinical trial that a new, vibration-based prevention technology tested in a neonatal intensive care unit (NICU) reduces apneic events and improves critical clinical parameters in prematurely born infants.

24 Nov 2015

Vibration-based therapy can successfully treat apnea events in preterm infants

Researchers from Beth Israel Deaconess Medical Center's Neonatal Intensive Care Unit (NICU), the Wyss Institute for Biologically Inspired Engineering at Harvard University and the University of Massachusetts Medical School have found that a vibration-based therapy known as stochastic resonance (SR) stimulation can successfully treat preterm infants experiencing apnea of prematurity (AOP), disrupted breathing, bradycardia (slowed heart rate) and oxygen desaturation (diminished oxygen levels).

23 Nov 2015

Allergan settles patent litigation with Amneal related to NAMENDA XR extended release capsules

Allergan plc, today announced that its subsidiaries Forest Laboratories, LLC and Forest Laboratories Holdings, Ltd., along with Adamas Pharmaceuticals, Inc., have entered into a settlement agreement with Amneal Pharmaceuticals LLC and related companies and subsidiaries.

10 Sep 2015